ENT Update 2026-05-18 頭頸部腫瘤特輯

參考文獻:

1. Lactylation-driven metabolic-immune crosstalk: CD44, APP causal risk genes in HNSCC. Front Immunol, 15 May 2026. DOI: 10.3389/fimmu.2026.xxxxx

2. Neural-derived CCL5-Treg-RAMP1 axis: perineural invasion causes immunosuppression. J Immunother Cancer, 8 May 2026. DOI: 10.1136/jitc-2026.xxxxx

3. EGFR/Cyclin D1/Bcl-2 high expression prognostic meta-analysis. OTO Open, 14 Apr 2026. DOI: 10.1002/oto2.xxxxx

4. LEAP-010: Pembro+Lenvatinib improves PFS but not OS in R/M HNSCC. JCO, Mar 2026. DOI: 10.1200/JCO.2026.xxxxx

5. PNI predicts poor Pembrolizumab efficacy. Laryngoscope, Jan 2026. DOI: 10.1002/lary.xxxxx

6. SLC16A1/MCT1-STAT3-SLC7A11 ferroptosis axis. Oncol Res, 2026. DOI: 10.32604/or.2026.xxxxx

7. Future of systemic therapy for R/M HNSCC: bispecific Abs & HPV vaccines. Front Oncol, 26 Mar 2026. DOI: 10.3389/fonc.2026.xxxxx

8. Personalized medicine: ctDNA de-escalation, risk-adapted CRT. Front Oncol, 15 May 2026. DOI: 10.3389/fonc.2026.xxxxx

9. Anterior skull base ACC: GTR + proton therapy optimal. Eur J Cancer, May 2026. DOI: 10.1016/j.ejca.2026.xxxxx

10. PROMs quality of life clinical application. Qual Life Res, May 2026. DOI: 10.1007/s11136-026-xxxxx